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Thiourea and guanidine derivatives are versatile compounds that have previously been synthesised 
for use in a variety of industries from materials manufacturing to medical research. It is this versatility 
which interests us in new possible pathways for these compounds, with the focus being the potential 
for advanced oncology research. This thesis discusses a single project in two halves, the first 
synthesising thiourea and guanidine derivatives, whilst the second half looks at the biological activity 
of those target molecules on three different ovarian cancer cell lines. Once synthesised, the derivative 
compounds were fully characterised by ¹H NMR, ¹³C NMR, elemental analysis, mass spectrometry and 
melting point analysis. Four additional compounds were included for biological testing, which 
comprise of thiourea and guanidine iridium complexes with alternative uses in OLED technology, 
whose ligand environment may also provide biological activity in mammalian cell cultures. There were 
no specific biological targets in which we were attempting to challenge but treated this research as a 
‘fishing trip’, to understand how well these thiourea and guanidine derivatives could perform as 
potential anticancer drugs.  
A panel of ovarian cancer cells consisting of adherent cell lines EFO-21 and EFO-27 followed by a 
suspension cell line (COLO-704) were investigated. Parental and cisplatin resistant sublines of these 
cells were used to observe effects of the thiourea and guanidine derivatives against cisplatin 
resistance. These cell lines were then dosed with each derivative from the compound library and their 
biological activity examined through MTT viability.  Cisplatin resistant cell lines were the focus due to 
the broad extent in which the anticancer drug has been researched, but also due to resistant 
mechanisms it has produced in human cancer cells. 
The investigated compounds showed promising results and displayed notable differences in their 
effects on reducing the viability of ovarian cancer cell lines, with the data collected potentially 




Table of Contents 
Abstract..................................................................................................................................................2 
Table of Contents.................................................................................................................................. 3 
List of Abbreviations..............................................................................................................................5 
Acknowledgements................................................................................................................................7 
Chapter 1: Introduction.........................................................................................................................8 
1.1 Thioureas and their applications......................................................................................................9 
1.2 Guanidines and their applications..................................................................................................11 
1.3 Iridium Complex compounds..........................................................................................................12 
1.4 Ovarian cell lines in cancer............................................................................................................ 16 
       1.4.1 Tackling resistance of Cisplatin in Ovarian cancer................................................................17 
1.5 Thesis Statement……………………………………………………………………………………………………………………….19 
Chapter 2: Synthesis and characterisation of Thiourea/Guanidine Derivatives and Iridium Complex 
Compounds as Potential Anticancer Drugs.........................................................................................20 
2.1 Introduction....................................................................................................................................20 
2.2 Materials and Apparatus................................................................................................................20 
2.3 Methods..........................................................................................................................................21 
2.3 Thioureas........................................................................................................................................21 
       2.3.1 Compound 1..........................................................................................................................21 
       2.3.2 Compound 2..........................................................................................................................22 
       2.3.3 Compound 3..........................................................................................................................23 
       2.3.4 Compound 4..........................................................................................................................24 
       2.3.5 Compound 5..........................................................................................................................25 
       2.3.6 Compound 6..........................................................................................................................26 
2.4 Guanidines......................................................................................................................................27 
       2.4.1 Compound 7..........................................................................................................................27 
       2.4.2 Compound 8..........................................................................................................................29 
       2.4.3 Compound 9..........................................................................................................................30 
       2.4.4 Compound 10........................................................................................................................31 
       2.4.5 Discussion - Thiourea & Guanidine Derivatives.....................................................................33 
2.5 Iridium Complex Compounds.........................................................................................................34 
       2.5.1 Synthesis Statement..............................................................................................................34 
       2.5.2 Precursor to Compound 11 and 12.......................................................................................34 
       2.5.3 Compound 11........................................................................................................................35 
4 
 
       2.5.4 Compound 12........................................................................................................................36 
       2.5.5 Compound 13........................................................................................................................37 
       2.5.6 Compound 14........................................................................................................................38 
Chapter 3: Analysis of compound anti-cancer activity through MTT cell viability assays.................40 
3.1 Introduction....................................................................................................................................40 
3.2 Materials and Apparatus................................................................................................................40 
3.3 Methods..........................................................................................................................................41 
      3.3.1 Cell Culture Techniques..........................................................................................................41 
      3.3.2 MTT Colorimetric Assay..........................................................................................................42 
3.4 Results: Effects of Thiourea and Guanidine Derivatives Through MTT Analysis.............................45 
       3.4.1 Compound 1 (carbothiomide) MTT Assay analysis................................................................45 
       3.4.2 Compound 2 and 7 (propylamine) MTT Assay analysis.........................................................45 
       3.4.3 Compound 3 and 8 (butylamine) MTT Assay analysis...........................................................46  
       3.4.4 Compound 4 and 9 (hexylamine) MTT Assay analysis...........................................................47 
       3.4.5 Compound 5 and 10 (benzylamine) MTT Assay analysis.......................................................48    
       3.4.6 Compound 6 (methylpyridin) MTT Assay analysis.................................................................49 
3.5 MTT analysis: Effects of Iridium Complex Compounds...................................................................50 
       3.5.1 Compound 11 and 12 (Thiourea/Guanidine IR-Complex’s MTT Assay analysis....................50 
       3.5.2 Compound 13 MTT Assay analysis.........................................................................................51 
       3.5.3 Compound 14 MTT Assay analysis.........................................................................................52 
3.6 Discussion….....................................................................................................................................53 
Chapter 4: Confocal microscopy of iridium complex compounds…...................................................58 
4.1 Introduction....................................................................................................................................58 
4.2 Materials and methods…................................................................................................................58 
4.3 Results.............................................................................................................................................60  
4.4 Discussion.......................................................................................................................................65 
Chapter 5: General discussion and outlook.........................................................................................67 
5.1 General discussion and conclusions………….....................................................................................67   
5.2 Future work…..................................................................................................................................68 
5.3 References......................................................................................................................................69 





List of Abbreviations: 
ACN - Acetonitrile  
CC - Column Chromatography  
+CDDP - Cisplatin Resistant  
¹³C NMR - Carbon-13 Nuclear Magnetic Resonance  
DCM - Dichloromethane  
DF - Dilution Factor  
DMF - Dimethylformamide  
4-DMAP - 4-(Dimethylamino)pyridine  
DMSO - Dimethyl sulfoxide  
EA - Elemental Analysis  
EI-MS m/z - Electron Impact Mass Spectrometry Mass/Charge Number of Ions  
Equiv - Equivalent  
FBS - Fetal Bovine Serum  
IC50 - 50% inhibitory concentration of cells 
IMDM - Iscove’s Modified Dulbecco’s Medium  
IR - Infrared Spectroscopy  
MeOH - Methanol 
MgSO₄ - Magnesium Sulphate  
MP - Melting Point Analysis 
MS - Mass Spectrometry  
MTT - 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
N₂ - Nitrogen 
NaHCO₃ - Sodium Bicarbonate 
NaOH - Sodium Hydroxide 
¹H NMR - Proton Nuclear Magnetic Resonance/Hydrogen-1 Nuclear Magnetic Resonance 
6 
 
NMR - Nuclear Magnetic Resonance Spectroscopy 
PBS - Phosphate-Buffered Saline  
Pen Strep - Antibiotic penicillin 100 IU/ml and Streptomycin 100mg/ml) 
PTL - Parental 
RF - Retardation Factor  
RT - Room Temperature 
SDS - Sodium Dodecyl Sulphate  
TCDI - 1,1’-Thiocarbonyldiimidazole 



















Firstly, I would like to thank SACO AEI Polymers UK for supporting me in funding this research project 
and all the colleagues who have supported me through the past two years. 
I would also like to thank my three supervisors at The University of Kent who have encouraged me 
with support and words of wisdom throughout my MSc. Dr Barry Blight who gave me the 
understanding I needed to grasp the complexities of Organic Chemistry and helped to motivate and 
spark my ideas, Dr Christopher Serpell for his continuing support throughout my final year and Dr 
Martin Michaelis for introducing me to the wonderful world of MTT assays along with his continuing 
support throughout my year in The School of Biosciences. 
I extend this thanks to all my friends in Lab 310 for their encouragement and laughter, especially 
Barbora Balonova who went out of her way to teach me the organic chemistry knowledge I had 
previously lacked. Also, to my friends in Lab 414, especially Hannah Onafuye, Joanna Bird and Evie 
Rogers for supporting me during many MTT assays, when balancing a full-time research career with a 
part time research degree proves to be a strenuous task. 
Finally, I would like to thank all my family for their unconditional support through all the stress, long 










Chapter 1: Introduction 
Organic and inorganic chemical synthesis is a fundamental component of the continuing research 
efforts which tackle the ever-challenging subject of cancer prevention. Evidence of cancer research 
pre-dates the 20th century with early surgical procedures carried out to remove tumours cell mass in 
a variety of cancers.57 Although it was not until the late 20th century when research into cancers 
bloomed, with the first major discovery in 1975 by Harold Varmus and J. Michael Bishop observing 
that normal cells are susceptible to alterations resulting in cancer.55 Since then, oncological 
technologies have continuously been explored with notable diversity of novel therapeutics and 
cellular pathways discovered in the first decade of the 21st century.56 Within these recent advances of 
novel therapeutics are two organic structures thiourea and guanidine, which have shown promise as 
potential anticancer agents. 
Thiourea, guanidine, and their derivatives are versatile compounds which have previously been 
synthesised in a variety of industries from materials/textile manufacturing to medical research.1 In 
their simplest form thiourea and guanidine are structurally similar as seen in Figure 1 although the 
properties between the two are significantly different. 
 
Figure 1. Structures of thiourea and guanidine in their basic form. 
 
The idea for this project sparked from initial research into organic light-emitting diode (OLED) 
technologies by Dr Barry Blight and Barbora Balonova (The Blight Chemistry Group, University of New 
Brunswick, Canada), where by derivatives of thiourea and guanidine were synthesised and 
incorporated into iridium complexes observed in Figure 2.82 The versatility of these structures spurred 
this research project to synthesise a variety of thiourea and guanidine derivatives and test them for 
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biological activity in human ovarian cancer cell lines. There were no specific biological targets in which 
we were attempting to challenge but treated this research as a ‘fishing trip’ to understand how well 
these thiourea and guanidine derivatives could perform as potential anticancer drugs.  
 
Figure 2. Structures of iridium centred complexes incorporating butyl-thiourea and butyl-guanidine 
derivatives. 
 
1.1 Thioureas and their applications: 
Ureas are widely used amide compounds with its neutral structure observed in Figure 3. While urea 
plays a role in the regulation of pH balance in humans,5 the structure has also been synthetically 
modified into a large array of derivatives for many industrial applications.2,4 Heavily used in the 
cosmetics industry, urea aids the rehydration of skin to combat dermatological conditions such as 
dermatitis in emollient treatments,2 with derivatives of urea also having successes in the treatment of 
cancers with positive inhibitory effects observed in rodent and human cancer models.6 These 
derivatives of urea include a variety of thiourea and guanidine compounds which will further discussed 
in this research project. 
 




While our attempts were to synthesis successful thiourea derivatives for ovarian cancer screening, 
there have been various derivatives of these synthesised with a wide array of targets in mind.3,4,7,8 
These include successes observed in the potency of non-nucleoside inhibitors of HIV-1 reverse 
transcriptase enzyme with effective doses exhibited in the nanomolar range,3 but research for 
thioureas also extends to insecticidal growth regulators,7 anti-inflammatory drugs,7 anticancer and 
antiviral effects,8 anti-thyroid properties1 and a more industrial materials application of thioureas 
being synthesised to aid the ozonolysis of olefin polymers.4 
Thioureas show promise of being successful anticancer candidates partly due to its sulfur group,38 with 
sulfur itself being a versatile and biologically important element to all living organisms.33 Sulfur has 
many forms including a variety of oxides and dioxide known for toxicity effects contributing to 
environmental concerns,34 but also within biotechnology sulfur has been incorporated into structures 
which have presented responses when screened for anti-inflammatory effects, and the inhibition of 
tumour growth.36 Sulfur is also favoured in a variety of biochemical applications, due to its versatility 
in the movement of electron pairs, being electrophilic or nucleophilic depending on its 
stereochemistry.33,35 
Previous sulfur based compounds for the application of ovarian cancer studies include sulofenur, a 
diarylsulfonylurea compound which in clinical trials was observed to have modest anticancer activity, 
against those treated previously with cisplatin.9 Although anticancer activity was observed, toxicity 
was also noted with patients suffering from anaemia and irregular liver functions,10 with similar 
toxicity alongside resistances observed throughout a variety of clinical trials.25 
In more recent studies, non-metal containing thiourea derivatives have been synthesised with an 
assortment of partnering organic structures, and screened via MTT cell viability assays against an array 
of human cell lines including breast and lung cancer lines, with promising IC50 values observed as low 
as 7-20 μM37 in some studies. Included in the diverse array of non-metal synthesis are a series of 
phosphonate thiourea derivatives which when screened against human breast, pancreatic and 
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prostate cancer cell lines, in an in vitro study achieved promising responses in IC50 values between 3-
14 μM.39 Achievable low-dose responses like these show promise for early research in to thiourea 
derivatives, while similar values to the above can be recognised across a further range of derivatives, 
including bis-thiourea structures for the application of human leukaemia cell lines with IC50 values as 
low as 1.50 μM40, but also in more aromatic derivatives of thiourea, synthesised with indole and 
adamantane compounds achieving a variety of positive IC50 values below 20 μM in breast, liver and 
lung cancers.41 This insight into derivatives of thiourea is just a fraction of research which has been 
completed over the past few years, as thioureas have become a popular focal point during the past 
decade. With low-dose responses achieved using a plethora of derivatives, it gives us confidence in 
the derivatives synthesised in this research project to achieve positive anticancer effects throughout 
the cell lines selected for screening. 
1.2 Guanidine’s and their applications: 
Sharing a similar structure to thiourea with the replacement of the sulfur ion with an NH group as seen 
in Figure 4, guanidine and its derivatives have great versatility throughout a variety of industries. The 
differing heteroatom in the structure lends guanidine a pKa of 13.6 making it a rather strong organic 
base,42 facilitating water solubility when protonated and known to exhibit strong interactions with 
DNA bases.44,43  
 
Figure 4. Highlighting the structural differences of thiourea and guanidine.  
 
These compounds have been observed with successes in catalytic synthesis for advances in green 
chemistry,29 antiviral responses observed in poliovirus,30 adhesive promotors in the materials 
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industry,31 synthesised derivatives with positive anticancer activity,32 but are also found in more 
natural sources like the human body, being mainly present in urine.27,28 Like ureas and thiourea groups, 
guanidines functionality has shown vast promise in the past decade, with advances in research leading 
to an array of derivatives with a main focal point being antimicrobial and anticancer properties, 
including successful observations in ovarian, lung and breast cancer cell lines achieved,26,32 further 
raising our interests as to the potentials which new synthesised derivatives could achieve and 
highlighting their biological importance. 
When examining the anticancer properties of various metal and non-metal guanidine derivatives we 
observe a similar pattern as seen in thioureas, being the success of low IC50 values achieved within in 
vitro studies throughout various human cancer cell lines.45 These include more heavily aromatic 
guanidine derivatives incorporating a ketone group ‘chalcones’ which have achieved IC50 values as 
low as 0.09 μM in human breast cancer cells,46 but also platinum centred derivatives assayed against 
ovarian and colorectal cancer cell lines achieving IC50 values below 5 μM in several synthesised 
variants.47 Successes like these support advances in synthesising further derivatives of guanidine 
compounds to target new areas of cancer therapeutics, and further proving the biological importance 
of these somewhat simple and easily manipulatable structures.  
Researching structures of the thiourea and guanidine derivatives synthesised in this research project 
was somewhat challenging. Whilst some of the compounds have previously been used for various 
biological purposes, there are limiting amounts of literature for the majority. When referencing all the 
derivative structures through SciFinder (Chemical Abstracts Service (CAS)) database it was observed 
at the time of synthesis that compounds 2, 4, 7 and 8 had no direct structural matches, thus suggesting 
these compounds which were synthesised are novel. 
1.3 Iridium Complex Compounds: 
The Iridium complexes used in this research project were synthesised and characterised by Barbora 
Balonova of The University of Kent/University of New Brunswick under the supervision of Dr Barry 
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Blight.82 The compounds and methods were prepared by Barbora as part of her research towards 
advancing organic light-emitting diode (OLED) technologies with curiosities leading to the potential 
observations of anticancer effects. These interests arose when discussing several observations around 
the research into these complexes; from a practical point of view, if these compounds were to be used 
in OLED screen technologies there is a risk of possible cytotoxic effects to the user if a screen were to 
break, resulting in contact with the compounds in question. From a research point of view due to 
successes in cancer therapeutics involving metal ion containing complexes,45,47 we would expect to 
observe a positive anticancer response from these iridium compounds. These compounds also have 
the advantage of long luminescence lifetimes when exposed to ultraviolet (UV) light, giving the 
opportunity to further be used in live cell imaging, without having to synthetically modify the 
compounds to accept fluorescent cellular probes like BODIPY. 
Luminescence is the excitation of molecules when exposed to UV light, which vibrate to a state 
whereby emission of light occurs at a longer wavelength then the absorbed light,59 making the 
luminescence properties visible to the human eye.  
Fluorescence and phosphorescence are both modes of luminescence but differ in their excitation 
lifetimes. Longer excitation lifetimes are acknowledged as phosphorescence and are defined by the 
ability of a compound to continue its emission properties even when the excitation promotor such as 
UV light has been terminated.66 The occurrence of phosphorescence is due to the excitation of an 
electron state known as a triplet state.68 A triplet state causes a lower but more stable energy state, 
giving a slower release of light emission and the effect of prolonged emission on removal of the 
excitation source.69 Shorter excitation lifetimes occur in fluorescence due to a singlet electron state, 
which has a higher and more unstable balance of energy acting as a fast and short-lived release of 
light emission, once the excitation source has been withdrawn the emission will cease.66 These two 











Figure 5. Jablonski Diagram of the electronic states of a molecule. Adapted from reference 86.86 
Whilst the market for fluorescent probes is vastly populated, one of the more commonly used probes 
includes BODIPY (Figure 6) which has become an ever-popular choice throughout the past two 
decades.60 Fluorescent probes like BODIPY allow structures which do not promote natural 
luminescence to be synthesised with the BODIPY compound attached.61 This gives an advantage within 
in vitro cell screening assays, allowing the structure to be traced throughout the cell under techniques 
such as confocal microscopy, demonstrated in Figure 7.85 
 
Figure 6. Chemical structure of BODIPY. 
Derivatives of BODIPY have had successes in a variety of screening applications, including monitoring 
the regulation of amino acid uptake to differentiate between ovarian cancer cells and non-cancerous 
cells through fluorescence uptake,62 and prove a useful tool within oncology research due to its 




Figure 7. Confocal image of SKOV-3 human ovarian cancer cells dosed with a BODIPY derivative, adapted from 
reference 85.85  
The iridium complexes have the advantage of being phosphorescent as demonstrated in Figure 8,82 
which provides a useful tool within research as compounds with these properties are used throughout 
numerous applications as effective biological probes for live cell imaging.58 The effectiveness of these 
complexes comes down to the emission properties, with iridium complexes in general exhibiting 
intense emission periods with high efficiency and long lifetimes.64 This establishment of highly efficient 
luminescence properties from iridium complexes has seen a surge in the need of these compounds 
for the development of high resolution OLED screen technologies,67 and biological probes with longer 








Figure 8. Image of an Iridium centred complex exposed to ambient light (left) and UV light (365nm) (right). 
Adapted from reference 82.82 
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It is expected the iridium complexes will be promising candidates for potency against ovarian cancer 
cells, due to a variety of metal ion containing compounds being heavily studied and proving their 
anticancer activity since the introduction of cisplatin in the 1960’s.25,84 Previous studies with iridium 
complexes have shown high potency towards cancer cells, with great potential due to a variety of 
abilities including adaptations of ligand bonding to alter their effectiveness and properties in biological 
systems,22 but also due to the fact iridium compounds are often associated with high cytotoxicity 
through the targeting and binding of DNA.24  This includes synthesis of iridium complexes for the 
application of ovarian cancer cells, where studies have observed promising IC50 values being obtained 
as low as 10.8 μM, when dosing human A2780 cell lines with an iridium centred complex.23  
With iridium-based complexes, derivatives of thioureas, and guanidines exhibiting positive effects 
during previous in vitro studies as potential anticancer agents, we posit that through synthesising a 
pair of derivatives incorporated in an iridium complex may further promote efficient low-dose 
responses, when screening these complexes against a panel of ovarian cancer cell lines. 
1.4 Ovarian cell lines in cancer: 
Ovarian cancer is an epithelial disease which is the sixth most common cancer in women across the 
globe,19 but also has the highest mortality rate within all gynaecological cancers.20 Current treatments 
include surgical procedures to remove tumour mass and chemotherapy’s which include platinum-
based and multiagent drugs,21 although whilst initial responses appear promising the cancer is known 
to persist in showing resistance 6-12 months post therapy completion.21 This aggressiveness of the 
disease has highlighted itself as a focal point for oncology developments, and the reason for this 
research project to potentially break resistant mechanisms which are regularly seen in clinical drugs 
such as cisplatin. 
Six human ovarian cancer cell lines were used for this research, where parental lines and cisplatin-
adapted resistant sublines were both screened to observe whether the resistant mechanisms would 
hinder toxicity effects of the synthesised compounds. The morphology of these cells visually followed 
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suit for what is expected of these ovarian cell lines from lab cultures seen in Figure 9. Although stress 
factors were not tested on these cells pre/post screening, there are a variety of techniques which have 
been carried out to observe stress factors on ovarian cancer cells. Stresses on tumorous ovarian cells 
have been shown to lead to a variety of outcomes including density, morphology and proliferation 
changes being altered by upregulation and downregulation of signalling pathways,48 whilst through 
mechanical analysis of cancer cells, it is possible to reveal that morphological changes are more likely 









Figure 9. Light microscope images of the 6 ovarian cell lines screened. 
 
1.4.1 Tackling resistance of Cisplatin in Ovarian cancer: 
Cisplatin is a successful platinum based anticancer drug widely used in the treatment of a variety of 
cancers including lung, bladder, testicular and ovarian cancers to name a few.11 Its developments 
began in 1845 when the initial structure of cisplatin was first synthesised by Michel Peyrone,12 (Figure 
10) although it was not until the 1960’s before the anticancer effects of cisplatin were discovered.12 
The mode of action for the success of cisplatin involves disrupting DNA repair mechanisms of cancer 
cells though purine bases crosslinking with cisplatin, inhibiting cellular replication finally resulting in 
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apoptotic cell death.13 Whilst initial patient responses to cisplatin are positive throughout several 
cancer types including ovarian cancers,16 there are negatives to the anticancer drug which include the 
development of resistant mechanisms and side effects such as immunosuppression, vomiting and 
nausea,15 alongside more severe side effects including nephrotoxicity, neurotoxicity and 
cardiotoxicity.14,15 Mechanisms of cisplatin resistance have become a dominant problem, particularly 
in ovarian cancers thus rapidly limiting its effectiveness in clinical environments.17 
It has been observed that resistance from cisplatin in ovarian cancers occurs after the initial treatment 
of screening therapeutic drugs, with a relapse in growth of tumour cells noted and known as acquired 
resistance.52 Other cancer types such as non-small celled lung cancers are intrinsically resistant to 
cisplatin.18 Acquired resistance can arise due to naturally occurring immune responses within the body 
causing reduced sensitivity to the therapeutic drug in use, thus diminishing the response rate,51,52 
while intrinsic resistance can occur due to complete failure of an anti-tumour response being 
promoted within the body.51 
 
 
Figure 10. Structure of Cisplatin 
 
While resistant mechanisms of cisplatin prove problematic, there have been a plethora of attempts to 
overcome this with new therapeutics aimed at cisplatin resistant ovarian cancer cells. Some of which 
include early in vitro studies which have identified areas of controlling metabolic enzyme regulation 
to be potential novel targets,53 but also through technological advances into liposomes being used as 
carriers of cisplatin, exhibiting positive in vitro progress with prolonged exposure of platinum levels 
observed within cells when comparing with a normally dosed cell.54 
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1.5 Thesis Statement 
The aim of this thesis is to synthesis a selection of organic thiourea and guanidine derivatives and test 
their effects on the viability of ovarian cancer cells. Included are several iridium complexes 
incorporating thiourea and guanidine based ligands, synthesised by Barbora Balonova of The 
University of Kent/University of New Brunswick under supervision of Dr Barry Blight.82  
The decision to focus our research on thiourea, guanidine and iridium complexes, was due to the great 
diversity of research areas in which these compounds have been applied to, alongside positive data 
generated from early in vitro screening assays into anticancer properties.4,22,30,38 Due to this previous 
research we decided the compounds presented, have promise to be screened against a panel of 
human ovarian cancer cell lines. Anticancer activity will be observed through an MTT cell viability assay 
to determine the compounds in vitro effectiveness, while comparing parental cell lines against 
cisplatin resistant sublines. Human ovarian cell lines were selected due to the aggressiveness of the 
disease and resistant mechanism, anticipating that our compounds could challenge these 
mechanisms. 
Ovarian cancer cells will be imaged once dosed with the iridium complexes due to the luminescent 
properties which these structures exhibit. We expect to observe correlations between the uptake of 
the compound in a cell and its effectiveness during the MTT assay. 
With the data collected through these experiments, we aim to identify derivatives of thiourea and 
guanidine which may be relevant with regards to the identification of new lead structures for drug 





Chapter 2: Synthesis and characterisation of Thiourea/Guanidine Derivatives and 
Iridium Complex Compounds as Potential Anticancer Drugs. 
2.1 Introduction  
To formulate our thiourea and guanidine derivatives, three known methods were used throughout 
the synthesis. The starting compound (1) was synthesised following methods from recent research 
into hydrogen bonding,70 whilst the thiourea derivatives were derived from this starting compound 
using the methods of Rakesh et al.,3 from research into the use of thiourea derivatives for HIV reverse 
transcriptase therapies. Once all thioureas were produced it was then possible to synthesise their 
guanidine substructures using the method of Blight et al.71 While these methods were followed, some 
of the synthesis steps were amended for the reaction times. 
2.2 Materials and Apparatus  
All solvents and starting materials were purchased from Fisher Scientific, Sigma-Aldrich, Arcos 
Organics and Alfa Aesar.  These materials were used as received from the supplier without any further 
purification methods carried out unless otherwise stated. All compound reactions were carried out 
under nitrogen atmosphere unless stated otherwise. 
NMR: ¹H NMR (400MHz) and ¹³C NMR (125MHz) spectra’s were recorded on a JEOL ECS 400 NMR 
spectrometer with deuterated solvents DMSO-d6 and chloroform-d used. Chemical shifts are recorded 
in ppm and peaks referred to as singlet (s), doublet (d), triplet (t), quartet (q) or multiplet (m). 
MS: Mass Spectra were recorded on a Bruker micrOTOF-Q Mass Spectrometer with a mass accuracy 
of 1-2 ppm. Peaks are referred to in mass to charge ratio (m/z).  
EA: Tested by Stephen Boyer at London Metropolitan University. Data is shown in percentage (%). 




CC: Completed using silica gel 60, 0.060-0.2mm (70-230 mesh) supplied by Alfa Aesar and fine sand 
supplied by Fisher Scientific and general-purpose cotton wool. 
TLC: Completed using pre-coated silica gel plates supplied by Macherey-Nagel (silica gel 60 with 
fluorescent indicator UV). 
 
2.3 Methods  
2.3 Thioureas  





Reagents and Conditions: (i) 2-aminobenzimidazol, TCDI (1.3equiv) (1,1’-thiocarbonyldiimidazole), 
acetonitrile, 50°C, 18 h. 
To a solution of 2-aminobenzimidazol (0.600 g, 4.506x10-3 mol) in acetonitrile (20 mL), 
thiocarbonyldiimidazole (1.043g, 5.858x10-3 mol) was added in 4 parts. The flask was sealed and 
placed in a 50°C oil bath for 18 h under a N₂ atmosphere. The formed precipitate was collected via 
suction filtration and additional acetonitrile used to wash the precipitate (3x30 mL) then dried via 
vacuum oven (40°C, overnight). Final product: pale yellow powder (0.654 g, 59% yield). 
¹H NMR: (400MHz, DMSO -d₆): 𝛿 8.54 (t, J = 1.0 Hz, 1H), 7.92 (t, J = 1.3 Hz, 1H), 7.60 (dd, J = 6.0, 3.2 
Hz, 2H), 7.33 (dd, J = 6.0, 3.2 Hz, 2H), 7.00 – 6.98 (m, 1H). ¹³C NMR: (125MHz, DMSO): 𝛿 179.34, 152.71, 
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136.71, 135.51, 129.77, 129.37, 124.34, 121.81, 118.32, 112.99. EA for C₁₁H₉N₅: Calculated: C; 54.31%, 
H; 3.73%, N; 28.79%, Obtained: C; 54.19%, H; 3.54%, N; 28.52%. MP: 188°C - 190°C. 





Reagents and Conditions: (i) DMF, propylamine (1.1equiv), 4-DMAP (N,N-dimethylpyridin-4-amine) 
(0.1equiv), 100°C, 15 h. 
To a solution of compound 1 (0.500 g, 2.055x10-3 mol) in DMF (15 mL), 4-DMAP (0.025 g 2.055x10-4 
mol) and propylamine (0.185 mL, 2.260x10-3 mol) were slowly added while stirring. The flask was 
sealed and placed in a 100°C oil bath for 18 h under N₂ atmosphere. The solution was then poured 
into a beaker of icy water (75 mL) and stirred until precipitation formed (1.5 - 2 h). The precipitate was 
collected via suction filtration then dried in a vacuum oven (40°C, overnight). TLC was carried out 
dissolving the sample in DCM and using a 1:3 ratio of ethyl acetate to hexane showing one sample 
trace with an RF value of 0.236.  Final product: pale yellow powder (0.303 g, 63% yield). 
¹H NMR: (400MHz, DMSO -d₆): 𝛿 11.18 (d, J = 60.2 Hz, 3H), 7.42 (dt, J = 6.7, 3.4 Hz, 2H), 7.13 – 7.07 (m, 
2H), 3.58 (dd, J = 12.5, 6.7 Hz, 2H), 1.71 – 1.57 (m, 2H), 1.03 – 0.89 (m, 3H). ¹³C NMR: (125MHz, 
chloroform-d): 𝛿 178.34, 148.35, 122.72, 111.30, 78.40, 76.84, 47.26, 22.22, 11.66. EA for C₁₁H₁₄N₄: 
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Calculated: C; 56.38%, H; 6.02%, N; 23.91%, Obtained: C; 56.49%, H; 6.11%, N; 23.86%. EI-MS m/z: 
Calculated: 234.32. Actual: 235.0997 [M+]. MP: 165°C - 170°C. 





Reagents and Conditions: (i) DMF, butylamine (1.1equiv), 4-DMAP (N,N-dimethylpyridin-4-amine) 
(0.1equiv), 100°C, 15 h. 
To a solution of compound 1 (0.500g, 2.055x10-3 mol) in DMF (18 mL), 4-DMAP (0.025 g, 2.055x10-4 
mol) and butylamine (0.223 mL, 2.260x10-3 mol) were slowly added. The flask was sealed and placed 
in a 100°C oil bath for 18 h under a N₂ atmosphere. The solution was then poured into a beaker of icy 
water (75 mL) and stirred until precipitation formed (0.5 - 1 h). The precipitate was collected via 
suction filtration then dried in a vacuum oven (40°C, overnight). Final product: White powder (0.372 
g, 73% yield). TLC was carried out dissolving sample in DCM and using a 1:3 ratio of ethyl acetate to 
hexane showing one sample trace with an RF value of 0.270. CC was carried out dissolving the 342 mg 
sample in DCM and using an eluent system of 1:3 ethyl acetate to hexane. Final product: white powder 
192 mg post CC giving a 56.14% column efficiency. 
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¹H NMR: (400MHz, DMSO -d₆): 𝛿 11.15 (s, 2.26H), 7.26 (d, J = 129.4 Hz, 3.51H), 3.63 (s, 1.95H), 1.50 (d, 
J = 93.6 Hz, 4H), 0.93 (s, 3H). EA for C₁₂H₁₆N₄: Calculated: C; 58.04%, H; 6.79%, N; 22.56%, Obtained: 
C; 57.95%, H; 6.32%, N; 22.7%. EI-MS m/z: calculated: 248.35. Actual: 249.1176 [M+]. MP: 165°C - 
170°C. 





Reagents and Conditions: (i) DMF, hexylamine (1.1equiv), 4-DMAP (N,N-dimethylpyridin-4-amine) 
(0.1equiv), 100°C, 15 h. 
To a solution of compound 1 (0.500 g, 2.055x10-3 mol) in DMF (15 mL), 4-DMAP (0.025 g, 2.055x10-4 
mol) hexylamine (0.297 mL, 2.260x10-3 mol) were slowly added. The flask was sealed and placed in a 
100°C oil bath for 18 h under a N₂ atmosphere. The solution was then poured into a beaker of icy 
water (75 mL) and stirred until precipitation formed (1 - 2 h). The precipitate was collected via suction 
filtration then dried in a vacuum oven (40°C, overnight). Final product: off-white powder (0.464 g, 81% 
yield). TLC was carried out dissolving the sample in DCM and using a 1:3 ratio of ethyl acetate to 
hexane showing one sample trace with an RF value of 0.342.  
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¹H NMR: (400MHz, DMSO -d₆): 𝛿 11.19 (d, J = 68.3 Hz, 2.20H), 7.78 – 6.67 (m, 3.81H), 3.55 (t, J = 43.6 
Hz, 2H), 1.62 (dd, J = 14.4, 7.0 Hz, 2H), 1.42 – 1.21 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). ¹³C NMR: (101 MHz, 
CHCL₃): 𝛿 122.69, 77.48, 77.16, 76.84, 45.63, 31.57, 28.79, 26.79, 22.70, 14.17. EA for C₁₄H₂₀N₄: 
Calculated: C; 60.84%, H; 7.29%, N; 20.27%, Obtained: C; 60.93%, H; 7.18%, N; 20.39%. EI-MS m/z: 
Calculated: 276.40. Actual: 277.1607 [M+]. MP: 117°C - 131°C. 






Reagents and Conditions: (i) DMF, benzylamine (1.1equiv), 4-DMAP (N,N-dimethylpyridin-4-amine) 
(0.1equiv), 100°C, 15 h. 
To a solution of compound 1 (0.147 g, 6.042x10-4 mol) in DMF (15 mL), 4-DMAP (0.007 g, 6.042x10-5 
mol) and benzylamine (0.073 mL, 6.646x10-4 mol) were slowly added. The flask was sealed and placed 
in a 100°C oil bath for 18 h under a N₂ atmosphere. The solution was then poured into a beaker of icy 
water (75 mL) and stirred until precipitation formed (6 - 8 h). The precipitate was collected via suction 
filtration then dried in a vacuum oven (40°C, overnight). Final product: pale yellow powder (0.121 g, 
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71% yield).  TLC was carried out dissolving the sample in DCM and using a 1:2 ratio of ethyl acetate to 
hexane observing one sample trace with an RF value of 0.235. 
¹H NMR: (400MHz, DMSO -d₆): 𝛿 11.43 (d, 2.43H), 7.25 (d, 9H), 4.95 (s, 1.77H). ¹³C NMR: (101 MHz, 
DMSO): 𝛿 148.05, 138.15, 128.49, 127.26, 127.13, 126.98, 121.61, 116.34, 110.98, 47.69. EA for 
C₁₅H₁₄N₄: Calculated: C; 63.81%, H; 5%, N; 19.89%, Obtained: C; 63.68%, H; 4.93%, N; 19.76%. EI-MS 
m/z: Calculated: 282.37. Actual: 283.1017 [M+]. MP: 183°C - 192°C. 





Reagents and Conditions: (i) acetonitrile, 2-amino-5methylpyridine, TCDI (1.3equiv), 50°C, 18 h. 
To a solution of 2-amino-5methylpyridine (0.600 g, 5.548x10-3 mol) in acetonitrile (15mL), 
thiocarbonyldiimidazole (1.285 g, 7.212x10-3 mol) was added in 4 parts. The flask was sealed and 
placed in a 50°C oil bath for 18 h under N₂ atmosphere. After 18 h precipitation was not observed, and 
the reaction was left to cool to room temperature for a further 6 h until precipitation formed. The 
precipitate was collected via suction filtration and additional acetonitrile used to wash the precipitate 
(3x30 mL) then dried via vacuum oven (40°C, overnight). Final product: pale orange powder (0.192 g, 
15% yield). TLC was carried out dissolving sample in DCM and using a 4:1 ratio of ethyl acetate to 
hexane observing one sample trace with an RF value of 0.20 and a second trace with an RF value of 
0.866. CC was carried out dissolving the 192 mg sample in DCM and using an eluent system of 4:1 
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ethyl acetate to hexane. 110 mg was collected post CC giving an efficiency of 57.29%. Post CC TLC 
showed a single sample trace with an RF value of 0.230. 
¹H NMR: (400MHz, DMSO -d₆): 𝛿 9.08 (s, 1H), 8.39 (d, 0.95H), 7.99 (d, 0.98H), 7.79 (d, 0.99H), 7.32 (d, 
1.98H), 2.41-2.28 (m, 6H). ¹³C NMR: (101 MHz, CHCL₃): 𝛿 179.40, 172.53, 153.45, 150.82, 145.30, 
139.91, 134.41, 130.11, 126.25, 124.83, 122.84, 77.48, 77.16, 76.84, 18.50, 18.38. EA for C₁₃H₁₄N₄: 
Calculated: C; 60.44%, H; 5.46%, N; 21.69%, Obtained: C; 56.6%, H; 4.20%, N; 18.19%. EI-MS m/z: 
Calculated: 258.0939 Actual: 259.1025 [M+]. MP: 131°C - 132°C. 
 
2.4 Guanidines  





Reagents and Conditions: (i) propylthiourea, CHCl₃, HgO (mercury (II) oxide) (1.4equiv), 2 M 
NH₃/MeOH, RT, 3 h.  
To a solution of compound 2 (0.200 g, 8.535x10-4 mol) in chloroform (20 mL), mercury (II) oxide (0.258 
g, 1.194x10-3 mol) and 2 M ammonia (4 mL) were added. The flask was sealed and stirred at room 
temperature for 3 h. The reaction solution was filtered through Celite® and washed with additional 
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chloroform (10 mL) with the solvent then removed under reduced pressure. Physical properties: 
Filtered solutions pale yellow/gold and pale yellow precipitate.  
The precipitate was dissolved in 2 M acetic acid (20 mL) and stirred at room temperature for 1 h. 
Reaction solution was then filtered through Celite® and adjusted to pH 8.0 by the addition of NaOH 
(10 M) to provoke precipitation. The formed precipitate was collected via suction filtration and dried 
in a vacuum oven (40°C, overnight). Final product: pale yellow powder (0.0861g, 46.5% yield). TLC was 
carried out dissolving the sample in DCM and using a 10:1 ratio of DCM to MeOH showing one sample 
trace with an RF value of 0.347.  
Standard extraction methods were carried out dissolving the 86 mg sample in DCM using saturated 
NaHCO3. Dried MgSO4 was added to collected organic layer then filtered. Solvent was then removed 
under reduced pressure. Final product: pale yellow powder (0.035 g, 43.75% extraction efficiency).  
¹H NMR: (400MHz, DMSO -d₆): 𝛿 11.18 (d, 3H), 7.42 (d, 2H), 7.13 – 7.07 (m, 2H), 3.58 (d, 2H), 1.71 – 1.57 (m, 
2H), 1.03 – 0.89 (m, 3H). ¹³C NMR: (101 MHz, DMSO -d₆): δ 159.07, 157.71, 132.22, 119.60, 118.99, 
114.92, 108.47, 42.14, 22.59, 11.40. EA for C₁₁H₁₅N₅: Calculated: C; 60.81%, H; 6.96%, N; 32.23%, 
Obtained: C; 57.64%, H; 6.96%, N; 28.81%. EI-MS m/z: Expected: 217.2760. Actual: 218.1409 [M+]. 














Reagents and Conditions: (i) Butylthiourea, CHCl₃, HgO (mercury (II) oxide) (1.4equiv), 2 M 
NH₃/MeOH, RT, 3 h.  
To a solution of compound 3 (0.200 g, 8.053x10-4 mol) in chloroform (20 mL), mercury (II) oxide (0.244 
g, 1.127x10-3 mol) and 2 M ammonia (4 mL) were added. The flask was sealed and stirred at room 
temperature for 3 h. The reaction solution was filtered through Celite® and washed with additional 
chloroform (10 mL) with the solvent then being removed under reduced pressure. Physical properties: 
Filtered solutions pale yellow/gold and yellow precipitate. 
The precipitate was dissolved in 2 M acetic acid (20 mL) and stirred at room temperature for 1 h. 
Reaction solution was then filtered through Celite® and adjusted to pH 8.0 by the addition of NaOH 
(10 M) to provoke precipitation. The formed precipitate was collected via suction filtration and dried 
in a vacuum oven (40°C, overnight). TLC was carried out dissolving sample in DCM and using a 10:1 
ratio of DCM to MeOH showing one sample trace with an RF value of 0.308. Final product: pale yellow 
powder (0.0756 g, 40.6% yield).  
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Standard extraction methods were carried out dissolving the 75 mg sample in DCM using saturated 
NaHCO3. Dried MgSO4 was added to collected organic layer then filtered. Solvent was then removed 
under reduced pressure. Final product: pale yellow powder (0.0491 g, 65.4% extraction efficiency). 
¹H NMR: (400MHz, DMSO -d₆): 𝛿 11.00 (s, 1H), 6.89 (t, 4H), 5.76 (s, 1H), 3.19 (q, 2H), 2.50 (DMSO), 
1.49 (m, 2H), 1.36 (m, 2H), 0.91 (t, 3H), 0.07 (s, 3H). ¹³C NMR: (101 MHz, CHCL₃): 𝛿 157.95, 157.69, 
120.76, 77.48, 77.16, 76.84, 41.65, 31.54, 29.87, 20.26, 13.89, 1.93, 1.17. EA for C₁₂H₁₇N₅: Calculated: 
C; 62.31%, H; 7.41%, N; 30.28%, Obtained: C; 50.52%, H; 7.33%, N; 18.67%. EI-MS m/z: Calculated: 
231.3030. Actual: 232.1575 [M+]. MP: 199°C - 214°C. 





Reagents and Conditions: (i) hexylthiourea, CHCl₃, HgO (mercury (ii) oxide) (1.4equiv), 2 M 
NH₃/MeOH, RT, 3 h.  
To a solution of compound 4 (0.210 g, 7.597x10-4 mol) in chloroform (25 mL), mercury (II) oxide (0.230 
g, 1.063x10-3 mol) and 2 M ammonia (4.7 mL) were added. The flask was sealed and stirred at room 
temperature for 3 h. The reaction solution was filtered through Celite® and washed with additional 
chloroform (10 mL) with the solvent then removed under reduced pressure. Physical properties: 
Filtered solutions pale yellow and pale yellow precipitate. 
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The precipitate was dissolved in 2 M acetic acid (20 mL) and stirred at room temperature for 1 h. 
Reaction solution then filtered through Celite® and adjusted to pH 8.0 by the addition of NaOH (10 M) 
to provoke precipitation. The formed precipitate was collected via suction filtration and dried in a 
vacuum oven (40°C, overnight). TLC was carried out dissolving the sample in DCM and using a 20:1 
ratio of DCM to MeOH showing three sample traces with RF values of 0.308, 0.493 and 0.790. Final 
product: pale yellow powder (0.0812 g, 41.2% yield).   
Standard extraction methods were carried out by dissolving the 105 mg sample in DCM and using 
saturated NaHCO₃. Dried MgSO₄ added to collected organic layer then filtered. Solvent was then 
removed under reduced pressure. Post extraction TLC showing one sample trace with an RF value of 
0.131. Final product: pale yellow (0.047 g, 44.76% extraction efficiency). 
¹H NMR: (400MHz, CHCL₃): 𝛿 7.41 (s, 1H), 7.26, 7.07 (s, 2H), 5.30, 3.90, 3.24 (t, 3H), 1.67-1.33 (m, 8H), 
0.91 (t, 3H), 0.07. ¹³C NMR: (101 MHz, DMSO): 𝛿 159.48, 158.10, 119.86, 119.51, 115.35, 108.97, 40.84, 
31.53, 29.77, 26.60, 22.59, 14.40. EA for C₁₄H₂₁N₅: Calculated: C; 64.83%, H; 8.16%, N; 27.00%, 
Obtained: C; 64.70%, H; 8.27%, N; 26.89%. EI-MS m/z: Calculated: 259.3570. Actual: 260.1890 [M+]. 
MP: 159°C - 164°C. 






Reagents and Conditions: (i) benzylthiourea, CHCl₃, HgO (mercury (ii) oxide) (1.4equiv), 2 M 
NH₃/MeOH, RT, 3 h. 
To a solution of compound 5 (0.240 g, 8.499x10-4 mol) in chloroform (25 mL), mercury (II) oxide (0.257 
g, 1.189x10-3 mol) and 2 M ammonia (5 mL) were added. The flask was sealed and stirred at room 
temperature for 3 h. The reaction solution was filtered through Celite® and washed with additional 
chloroform (10 mL) with the solvent then removed under reduced pressure. Physical properties: 
Filtered solutions pale green/yellow and green oily precipitate. 
The precipitate was dissolved in 2 M acetic acid (20 mL) and stirred at room temperature for 1 h. 
Reaction solution then filtered through Celite® and adjusted to pH 8.0 by the addition of NaOH (10 M) 
to provoke precipitation. The formed precipitate was then collected via suction filtration and dried in 
a vacuum oven (40°C, overnight). Final product: pale yellow powder (0.201 g, 78.8% yield). TLC carried 
out dissolving sample in DCM and using a 20:1 ratio of DCM to MeOH showing one sample trace with 
an RF value of 0.188. 
Standard methods of extraction were carried out dissolving the 201 mg sample in DCM and using 
saturated NaHCO₃. Dried MgSO₄ added to collected organic layer then filtered. Solvent was then 
removed under reduced pressure. Final product: pale yellow (0.040 g, 19.90% extraction efficiency).  
¹H NMR: (400MHz, CHCL₃,): 𝛿 7.37-7.30 (m, 7H), 7.26 (CHCL₃), 7.08 (m, 2H), 5.30, 4.50 (s, 2H), 3.89, 
1.25, 0.87, 0.07. ¹³C NMR: (101 MHz, DMSO): 𝛿 159.25, 157.99, 140.57, 128.77, 127.66, 127.21, 119.97, 
115.53, 44.16. EA for C₁₅H₁₅N₅: Calculated: C; 67.90%, H; 5.70%, N; 26.40%, Obtained: C; 67.75%, H; 







2.4.5 Discussion - Thiourea & Guanidine Derivatives 
Five thiourea derivatives were successfully synthesised with yields as high as 81%. We found the most 
successful route of synthesis was by addition of differing amine chains as seen in compounds 2-5, 
using a slight modification of known methods by Rakesh et al.,3 with compound 1 as the precursor. 
Compound 6 used an addition of a 2-amino-5methylpryidine which was not successful in its synthesis 
when using the same methods as compounds 2-5, even after several attempts in amending reaction 
and precipitation times. Due to being unsuccessful the methods of Mukherjee et al.,70 as used in 
compound 1 were then applied and the 2-aminobenzimidazol structure replaced with a 2-amino-
5methylpryidine compound, which whilst achieving a low yield of 15% still demonstrated through 
analysis that the structure was successfully synthesised. 
Once the thioureas had been synthesised and characterised we then carried out the methods of Blight 
et al.71 to successfully produce four guanidine derivatives from compounds 2-5 with a mixture of high 
and low yields. Synthesis was also attempted using compound 6 to gain a further guanidine structure, 
but after several attempts it was not possible to collect a clean compound with high purity using this 
method. 
During the initial synthesis stages, we attempted to design further thiourea derivatives using both 
methods from Rakesh et al.,3 and Mukherjee et al.,70 with additions of aminopyridine involving methyl 
and chlorine moieties. Unfortunately, these were unsuccessful in producing clear spectra during NMR 








2.5 Iridium Complex Compounds  
2.5.1 Synthesis Statement 
Compounds 11 to 14 were successfully synthesised and characterised by Barbora Balonova during her 
PhD carried out between the University of Kent, UK and the University of New Brunswick, CA.82 While 
her research into these structures continues, all synthesis methods and analysis are correct at the time 
of this research project. 
2.5.2 Precursor to Compound 11 and 12 
Ir-chloro-bridged dimer4: 
 
Reagents and Conditions: (i) Iridium(lll) chloride, 2-phenylpyridine, 2-ethoxyethanol : water (3:1), 
reflux, 24 h. 
To a solution of 2-ethoxyethanol (15 mL), 2-phenylpyridine (0.69 mL, 4.85 mmol), iridium (III) chloride 
trihydrate (0.81 g, 2.31 mmol) were dissolved with an addition of water (5 mL). The flask was sealed 
and placed in an oil bath for 24 h under a N₂ atmosphere. The flask was left to cool to room 
temperature, forming a yellow precipitate which was collected via suction filtration and thoroughly 
washed with additional water (20 mL), ethanol (20 mL) and acetone (20 mL) then dried via vacuum 
oven (40oC, 24 h). Final product: Canary yellow powder (1.05 g, 84% yield) with no further purification 
required. 
1H NMR: (400MHz, 298K, chloroform-d): 𝛿 5.92-5.94 (s, 1H), 6.55-6.58 (t, 1H), 6.73-6.79 (m, 2H), 7.48-
7.50 (d, 1H), 7.72-7.76 (t, 1H), 7.86-7.88 (d, 1H), 9.23-9.25 (d, 1H). 13C NMR: (100MHz, 298K, 
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chloroform-d): 𝛿 168.97, 152.13, 145.79, 144.14, 136.61, 131.03, 129.54, 124.05, 122.57, 121.28, 
118.85. 
 
2.5.3 Compound 11  
Iridium (ppy)-butyl-thiourea 
 
Reagents and Conditions: (i) iridium (ppy)-chloro dimer, butylthiourea, K2CO3, toluene, reflux, 22 h. 
To a solution of 25 mL dry toluene, Iridium (ppy)-chloro dimer (145 mg, 1.35 x 10-4 mol) and 
butylthiourea (83 mg, 2.5 equiv) were added with potassium carbonate (184 mg). The mixture was 
stirred for 22 h under N2 atmosphere resulting in a bright yellow solution. The reaction mixture was 
cooled to room temperature and diluted with dichloromethane. Extraction with water (2x20 mL) 
removed the excess base. The organic layers were separated, combined and dried over MgSO4 
resulting in a yellow solid which was further purified. Solids were dissolved in chloroform and hexane 
was added dropwise while stirring, until a precipitate formed. Solids were filtered via suction filtration 
and dried under vacuum on Schlenk line for 24 h. Final product: bright yellow powder in (53 mg, 53% 
yield). 
EA for C34H31IrN6S: Calculated: C, 54.60; H, 4.18; N, 11.24. Obtained: C, 54.26; H, 4.11; N, 11.22. EI-

















Reagents and Conditions: (i) IR-chloro-bridged dimer4 ([Ir(ppy)2Cl]2), butylguanidine, K2CO3, toluene, 
110°C, 16 h. 
To a solution of 12 mL of dry toluene, Iridium dimer [Ir(ppy)₂CL]₂ (39.7 mg, 3.70 x10-5 mol), 2.5 
equivalents of compound 8 and 10 equivalents of potassium carbonate were slowly added. The flask 
was sealed and placed in a 110°C oil bath with the addition of an N2 atmosphere and stirred overnight. 
The solvent was then evaporated under a reduced pressure forming a precipitate. To dissolve the 
solid, 8-12 mL of dichloromethane was added, then to remove excess base the solution was extracted 
with water (3x20 mL). The organic layers of the extraction were combined, and the solvent evaporated 
under a reduced pressure. Column chromatography was carried out to purify the sample using silica 
gel and an eluent system of 10:0.25 - 10:1 DCM to MeOH. Final product: Bright yellow powder and a 
44% yield. 
1H NMR (600 MHz, 298 K, chloroform-d): δ 8.68 (dd, J = 5.9, 0.8 Hz, 1H), 8.15 – 8.04 (m, 1H), 7.88 (d, J 
= 8.1 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.73 (td, J = 8.0, 1.6 Hz, 1H), 7.67 (dd, J = 7.4, 1.3 Hz, 1H), 7.60 (d, 
J = 7.8 Hz, 2H), 7.15 (d, J = 7.9 Hz, 1H), 7.08 (ddd, J = 7.3, 5.9, 1.3 Hz, 1H), 7.01 – 6.87 (m, 4H), 6.79 
(dtd, J = 20.6, 7.4, 1.3 Hz, 2H), 6.68 – 6.62 (m, 1H), 6.43 (dd, J = 7.6, 0.8 Hz, 1H), 6.24 – 6.19 (m, 1H), 
6.15 (s, 1H), 6.09 (d, J = 8.3 Hz, 1H), 5.72 (s, 1H), 4.56 (s, 1H), 3.04 – 2.78 (m, 2H), 1.41 (ddd, J = 14.0, 
7.1, 3.5 Hz, 2H), 1.23 (dd, J = 14.0, 6.6 Hz, 2H), 0.79 (t, J = 7.3 Hz, 3H). 
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13C NMR (100 MHz, 298K, chloroform-d): δ 169.15, 168.17, 153.61, 151.88, 151.57, 150.01, 148.83, 
147.52, 144.62, 144.47, 141.20, 136.82, 136.51, 133.05, 132.01, 129.72, 124.57, 124.01, 122.63, 
121.84, 121.62, 121.33, 121.08, 118.80, 116.86, 110.65, 77.16, 41.06, 30.85, 20.05, 13.76. EI-MS m/z 
calculated: 731.2348 found: 732.2450 [M+]. Anal. calcd. for C12H14N5: C, 55.87; H, 4.41; N, 13.41. 
Found: C, 55.96; H, 4.31; N, 13.35. 
 





Reagents and Conditions: (i) 5-iodopyrimidine-2,4-diamine, 2-formylphenyl boronic acid, K2CO3, 
Pd(PPh3)4, reflux, 3 h. 
To a solution of a 3:1 mixture of dioxane (9 mL) with an addition of water (3 mL), 5-iodopyrimidine-
2,4-diamine (197 mg, 8.34x10-4 mol), 2-formylphenyl boronic acid (182 mg, 1.21 mmol), potassium 
carbonate (0.461 g, 3.33 mmol) followed by triphenylphosphine palladium (1.4 mg, 0.5 mol%) were 
all added. The flask was sealed with an addition of a reflux and placed in an oil bath for 3 h under a N₂ 
atmosphere. The flask was then left to cool to room temperature and submerged in a chilled bath to 
form precipitate, which from this was filtered then washed with water (2x30 mL). Lastly the precipitate 
was sonicated in water then dried via vacuum oven (40oC, 24 h). Final product: Bright yellow powder 
(82 mg, 50% yield). 
1H NMR: (400 MHz, 298K, DMSO-d6,): 𝛿 9.86 (s, 1H), 9.48 (s, 1H), 8.70-8.72 (d, 1H), 8.14-8.16 (d, 1H), 
7.88-7.90 (t, 1H), 7.63-7.67 (t, 1H), 7.16 (br, s, 2H, NH2). 13C NMR: (100 MHz, 298 K, DMSO-d6): 𝛿 
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163.68, 161.43, 158.80, 158.50, 132.58, 132.22, 129.33, 126.43, 124.43, 124.41, 120.35, 107.00. EI-
MS m/z calculated: 196.07 found: 197.08 [M+]. MP: > 280oC. EA for C11H8N4: Calculated: C, 67.34; H, 
4.11; N, 28.55. Obtained: C, 67.19; H, 4.25; N, 28.35. 
 
2.5.6 Compound 14  




Reagents and Conditions: (i) 2,6-diaminopyridine, N-iodosuccineimide (2.2 equiv), DMF, -30oC, 1 h. 
To a solution of DMF (20 mL), 2,6-diaminopyridine (0.99 g, 9.09 mmol) in dry DMF (28 mL) and N-
iodosuccineimide (4.5 g, 19.9 mmol) were slowly added over 1 h at -30oC in a cooling bath on dry ice. 
The flask was then raised to cool to room temperature and stirred for a further 1 h with the solution 
then being poured into a beaker of icy water followed by stirring for 20 mins. The formed precipitate 
from this was collected via suction filtration and washed with water (2x20 mL) followed by pentane 
(2x15 mL) before being dried via vacuum oven (40°C, overnight). Final Product: grey solid (3.08 g, 94% 
yield). 
1H NMR: (400 MHz, 298 K, DMSO-d6): 𝛿 7.73(s, 1H), 5.71(s, 4H) 13C NMR: (100 MHz, 298K, DMSO-d6): 












Reagents and Conditions: (i) 3,5-diiodo-2,6-pyridinedimine, 2-formylphenylboronic acid, K2CO3, 
Pd(PPh3)4, dioxane : water (3:1), reflux, 3 h. 
To a solution of 3:1 dioxane:water, 3,5-diiodo-2,6-pyridinediamine (0.43 g, 1.21 mmol), 2-
formylphenylboronic acid (0.36 g, 2.42 mmol), potassium carbonate (2 g, 0.014 mol) and 
triphenylphosphine palladium (0.02 g, 1.73 x 10-5mol) were added in a sealed flask with an addition of 
a reflux and placed in an oil bath for 3 h. The flask was then raised to cool to room temperature and 
left to stir for 1 h with the formed precipitate then collected via suction filtration and washed with 
water (2x15 mL) before being dried via vacuum oven (40°C, overnight). Final Product: Yellow powder 
(98% yield). 
1H NMR (400 MHz, 298 K, chloroform-d): δ 7.86-7.90 (t, 2H), 8.03-8.07(t, 2H), 8.21-8.22(d, 2H), 8.90-









Chapter 3: Analysis of compound anti-cancer activity through MTT cell viability assays 
3.1 Introduction 
To examine the biological activity of the compounds synthesised in chapter 2, they were tested on the 
viability of human ovarian cancer cell lines EFO-21, EFO-27 and COLO-704, including their cisplatin-
adapted sublines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphennyltetrazolium bromide) (MTT) 
assay. Cisplatin resistant sublines were the focal point due to the broad extent in which the anticancer 
drug has been used and researched, but also due to resistant mechanisms it has produced in human 
cancer cells. 
When considering the options for cell viability assays there are a variety of techniques used across a 
wide array of research applications, including MTT, XTT, MTS and Raman Microscopy.72 The MTT 
protocol was selected for this cell viability assay due to being one of the most commonly used and 
robust techniques,72 whilst allowing for ease of large batch testing with multiple compound types.73 
The assay principle is based on metabolization of the yellow MTT reagent into a purple insoluble 
formazan compound within the mitochondria of viable cells.74,75 This colour change from yellow to 
purple enables for the collection of rapid and coherent cell proliferation data.65 
3.2 Materials and Apparatus 
All compounds were dissolved in DMSO and stored at room temperature prior to the start of the MTT 
assays.  
The cell lines EFO-21, EFO-27 and COLO-704 were purchased from DSMZ (Braunschweig, Germany). 
The cisplatin-resistant sublines EFO-21rCDDP2000 (adapted to 2,000 ng/mL cisplatin), EFO-27rCDDP2000, 
COLO-704rCDDP1000 were obtained from the Resistant Cancer Cell Line (RCCL) collection 
(https://research.kent.ac.uk/ibc/the-resistant-cancer-cell-line-rccl-collection). 
All cell lines were cultured in IMDM (Gibco™ Life Technologies) which was supplemented with 10% 
(v/v) foetal bovine serum (FBS) (Sigma-Aldrich), 100 IU/mL penicillin (Sigma-Aldrich) and 100 mg/mL 
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streptomycin (Sigma-Aldrich). PBS tablets (Oxoid Limited) were used to wash all cell lines prior to 
dissociation. Trypsin (0.25% w/v) (Gibco Life Technologies) was used for dissociation of all adherent 
cell lines cultured in T25 flasks. MTT (SERVA Electrophoresis – Universal Biologicals) solution was made 
up in PBS followed by sterile filtering using a vacuum pump. 20% (w/v) SDS (Sigma-Aldrich) solution 
was prepared using DMF and distilled water in a 1:1 ratio, followed by adjusting the pH to 4.0 using a 
1M stock solution of hydrochloric acid (Fisher Scientific). For conducting cell counts, FLUKA Trypan 
Blue (Sigma-Aldrich) was added to the cells before using a haemocytometer under light microscopy. 
A BMG Labtech Fluostar (Omega Plate Reader) was used to read all the assay plates. Multichannel and 
single tip pipettes were used and purchased from Eppendorf. Clear polystyrene T25cm² tissue culture 
flasks using a ventilation cap, sterile stripettes and falcon tubes were purchased from Sarstedt. 96 well 
plates used during all MTT assays were purchased from Greiner Bio-one. Sterile medium reservoirs 
and drug blocks were used from autoclaved lab supplies. 
3.3 Methods 
3.3.1 Cell Culture Techniques 
All cell lines were cultured in a T25 flask using 10 mL cell culture medium. EFO-21 and EFO-27 cell lines 
are adherent to surfaces and were passaged as follows; once the T25 flasks had reached around 80% 
confluence the medium was removed, and the cells were washed with 2 mL PBS. The PBS was then 
removed and 2 mL of Trypsin (0.25%) was added, followed by the flask being incubated at 37°C/5% 
CO₂ for around 5 minutes. Once detachment of the cells had been achieved the cells were re-
suspended in 8 mL cell culture medium. From this the cells could be used for counting, seeding in 96 
well plates or passaging to continue the tissue culture process. 
The COLO 704 cells are a suspension cell line and required a modified culture method from the EFO 
lines. Once the T25 flasks had reached around 80% confluence the cells/medium were transferred to 
15 mL falcon tubes followed by centrifuging for 3 minutes at 1000 rpm. Once a pellet of cells had 
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formed at the base of the falcon the medium was removed, cells dislodged and 2 mL PBS added 
followed by centrifuging for 3 minutes at 1000 rpm. Once a pellet had reformed the PBS was removed 
and the cells dislodged followed by adding 1 mL Trypsin (0.25%) and finally adding 9 mL of prepared 
IMDM medium. From this the cells could be used for counting, seeding in 96 well plates and re-plating 
in a fresh T25 for continuing the tissue culture process. 
3.3.2 MTT colorimetric assay 
Medium Setup: 
To prevent evaporation of medium in the cell/drug wells, 50 μL of cell culture medium was pipetted 
into the outer wells of the 96 well plate. Two controls were also set up being 50μl pipetted in row B2-
G2 for a positive control and 100 μL pipetted in row B11-G11 for a negative control. For every MTT 
assay the plates were all initially prepared using this method as seen in Figure 11. 
Compound Setup: 
All compounds had a starting dose of 50 μM or 20 μM with some using an 8-fold serial dilution of 1:2 
or 1:4. These dilutions were made up in a 2 mL drug block with 50 μL of these dilutions being dispensed 
into the appropriate wells. Two compounds were plated on one 96 well plate for each cell line as seen 
in Figure 12.  
Cell line setup: 
Once culturing methods were completed as stated in chapter 3.3.1, 20 μL of re-suspended cells were 
dispensed into an Eppendorf where a solution of 40 μL Trypan blue and 20μl PBS were added. This 
cell solution was then viewed under light microscope on a haemocytometer to collect the cell count, 
then calculating dispensing 7000 cells per 50 μL into each well. 50 μL of cells were dispensed in the 





























Once all cells had been dispensed the plates were incubated at 37°C/5% CO₂ for 5 days before adding 
25 μL of MTT solution to each well followed by a 4 hour incubation period at 37°C/5% CO₂ and adding 
100 μL of 20% SDS solution to each well followed by a further incubation overnight at 37°C/5% CO₂. 
 
Analysis of MTT plates: 
Following overnight incubation, the MTT plates were analysed using an Omega Plate Reader at 600 

















3.4 Results: Effects of Thiourea and Guanidine Derivatives Through MTT Analysis. 
3.4.1 Compound 1 (carbothiomide) MTT Assay analysis 
Of compound 1 a stock solution was worked up in DMSO and a 50 μM start concentration with a 1:4 
dilution was plated across all cell lines. Figure 14 displays data from compound 1 with very similar 
patterns observed between EFO-21 PTL and EFO-27 PTL cell lines whilst greater stability is seen their 
+CDDP sublines. Whilst averages between the PTL and +CDDP sublines are very similar the margin of 
error is far higher in both PTL cell lines. COLO-704 PTL is observed to be the least sensitive cell line to 








Figure 14. IC50 data of compound 1 against all 6 cell lines. Y-axis represents the concetration of compound 
needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with error bars given 
for the standard deviation of the three repeats. 
 
3.4.2 Compound 2 and 7 (propylamine) MTT Assay analysis 
Of compound 2 and compound 7 stock solutions in DMSO were worked up and from this a 50 μM start 
concentration with a 1:4 dilution was plated across all cell lines. Figure 15 highlights data from the 
derivatives synthesised with a propylamine chain. Throughout all the cell lines greater sensitivity is 
observed in the thiourea derivative, compound 2 whilst similar low dose IC50 averages are seen in all 
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cell lines apart from a slight reduction in sensitivity of EFO-27 +CDDP subline. Throughout the analysis 
of the guanidine derivative compound 7 the 3 cell lines displayed similar responses with greater 









Figure 15. IC50 data of compound 2 and compound 7 against all 6 cell lines. Y-axis represents the concetration 
of compound needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with 
error bars given for the standard deviation of the three repeats. 
 
3.4.3 Compound 3 and 8 (butylamine) MTT Assay analysis 
For both compound 3 and compound 8 a stock solution in DMSO was worked up and a 50 μM starting 
concentration with a 1:2 dilution was plated for compound 3, whilst a 1:4 dilution was plated across 
all cell lines for compound 8. Figure 16 presents IC50 values for the derivatives synthesised using a 
butylamine chain with cell lines following a similar pattern seen in Figure 15. Greater sensitivity is 
displayed when the cells are dosed with the thiourea derivative compound 3 whilst similar averages 





Figure 16. IC50 data of compound 3 and compound 8 against all 6 cell lines. Y-axis represents the concetration 
of compound needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with 
error bars given for the standard deviation of the three repeats. 
 
3.4.4 Compound 4 and 9 (hexylamine) MTT Assay analysis 
Figure 17 displays data for the derivatives synthesised with a hexylamine chain, with both compound 
4 and compound 9 worked up to a stock solution in DMSO and from this a 50 μM start concentration 
with a 1:2 dilution was plated across all cell lines. Whilst Figure 15 and Figure 16 select for greater 
sensitivity in the thiourea derivative compounds, Figure 17 observes greater sensitivity in the 
guanidine derivative compound 9 throughout all cell lines. A closer examination notes that all PTL cell 
lines dosed with both derivatives show greater sensitivity when compared to their +CDDP sublines 




Figure 17. IC50 data of compound 4 and compound 9 against all 6 cell lines. Y-axis represents the concetration 
of compound needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with 
error bars given for the standard deviation of the three repeats. 
 
3.4.5 Compound 5 and 10 (benzylamine) MTT Assay analysis 
Of both compound 5 and compound 10 a stock solution in DMSO was worked up and from this a 50 
μM start concentration with a 1:2 dilution for the two was plated across all cell lines. Figure 18 depicts 
analysis of the derivatives synthesised using a benzylamine chain, with greater sensitivity to the 
thiourea derivative compound 5 observed throughout all cell lines, with EFO-21 and EFO-27 showing 
greater sensitivity in the PTL cell line. While the majority of data is consistent, there is a high error 
margin throughout EFO-21 +CDDP, EFO-27 PTL and EFO-27 +CDDP lines although which is not 




Figure 18. IC50 data of compound 5 and compound 10 against all 6 cell lines. Y-axis represents the concetration 
of compound needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with 
error bars given for the standard deviation of the three repeats. 
 
3.4.6 Compound 6 (methylpyridine) MTT Assay analysis  
A stock solution in DMSO was worked up of compound 6 and from this a 50 μM starting concentration 
was used with a 1:2 dilution plated across the six cell lines. Figure 19 highlights IC50 values from the 
thiourea derivative compound 6 with a variety of differences noted. Whilst EFO-21 PTL and EFO-27 
PTL cell lines were less sensitive to compound 6 then their +CDDP sublines, COLO-704 PTL cells were 
more sensitive than their +CDDP sublines. COLO-704 PTL and +CDDP sublines are observed to have 
greater sensitivity overall than both EFO-21 and EFO-27 PTL/+CDDP with a lower dose concentration 




Figure 19. IC50 data of compound 6 against all 6 cell lines. Y-axis represents the concetration of compound 
needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with error bars given 
for the standard deviation of the three repeats. 
 
3.5 MTT analysis: Effects of Iridium Complex Compounds  
3.5.1 Compound 11 and 12 (Thiourea/Guanidine IR-Complex’s MTT Assay analysis) 
Of compound 11 a stock solution in DMSO was worked up with a 50 μM starting concentration used 
with a 1:4 dilution plated for EFO-21 PTL and EFO-27 PTL cell lines whilst a 1:2 dilution plated for the 
remaining cell lines. For compound 12 a stock solution in DMSO was worked up and from this a 20 μM 
starting concentration with a 1:2 dilution was plated across the six cell lines. Figure 20 displays data 
from the thiourea and guanidine iridium complex’s, throughout all cell lines there was an observed 
sensitivity to the guanidine complex compound 12 with consistent IC50 concentrations noted 
throughout all PTL and +CDDP sublines when comparing to the thiourea complex compound 11. 
Analysis of compound 11 against all cell lines observed all +CDDP sublines to be less sensitive in 
comparison to all PTL’s lines, although COLO-704 PTL and +CDDP sublines were observed to have 





Figure 20. IC50 data of compound 11 and compound 12 against all 6 cell lines. Y-axis represents the concetration 
of compound needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with 
error bars given for the standard deviation of the three repeats. 
 
3.5.2 Compound 13 MTT Assay analysis  
A stock solution in DMSO was worked up of compound 13 and from this a 50 μM starting 
concentration was used with a 1:2 dilution plated across the six cell lines. EFO-21 +CDDP and EFO-27 
+CDDP sublines are observed in Figure 21 to have a slightly greater sensitivity then their PTL cell lines, 









Figure 21. IC50 data of compound 13 against all 6 cell lines. Y-axis represents the concetration of compound 
needed to achieve the IC50 value in μM. X-axis represents the cell lines used in the assay, with error bars given 
for the standard deviation of the three repeats. 
 
3.5.3 Compound 14 MTT Assay analysis 
Of compound 14 a stock solution in DMSO was worked up with a 50 μM starting concentration used 
with a 1:2 dilution plated across the six cell lines. Figure 22 exhibits the effects of compound 14 against 
all cell lines. EFO-21 and EFO-27 PTL cell lines show similar patterns to compound 13 where by their 
+CDDP subline is observed to show greater sensitivity to compound 14 then both the PTL cell lines. 
COLO-704 cell lines slightly differ with the PTL cell line showing greater sensitivity then the +CDDP 
subline but also EFO-21 and EFO-27 PTL cell lines. The COLO-704 +CDDP subline was observed to have 







Figure 22. IC50 data of compound 14 against all 6 cell lines. Y-axis represents the concetration of compound 
needed to achieve an IC50 value in μM. X-axis represents the cell lines used in the assay, with error bars given 
for the standard deviation of the three repeats. 
 
3.6 Discussion 
Evaluation of the MTT cell viability assays reveals a vast array of promising IC50 data ranging between 
0.8-35 μM. Throughout compounds 1-14 significant differences in toxicities are noted as seen in Figure 
23, providing us with a theraputic window observing compounds displaying selectivity rather than 
killing all cells outright. By calculating the standard deviation of the 3 repeat assays per cell 
line/compound, we were able to include error margins to figures 14-22. 
When comparing the overall effectiveness of the thiourea and guandine derivatives which share the 
same amine chains, the data collected is varied with no clear indication whether thiourea or guanidine 
structures are more successful overall (Figure 23/Table 1). The thiourea derivatives synthesised with 
a propylamine, butylamine and bezylamine chains, compounds 2, 3 and 5 displayed greater sensitivity 
to all six cell lines than their guanidine counterparts compound 7, 8 and 10. It was expected the 
thiourea derivative compound 4 (hexylamine) may follow suit, but this displayed greater sensitivity in 
its guanidine counterpart compound 9, as did the iridium complex compound 12. 
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Closer examination of the data highlights compounds 2, 3 and 12, which share similar low dose 
responses between 0.8-1.5 μM which are not displayed in the other 11 compounds (Figure 23). 
Alongside the IC50 values, compounds 2 and 3 were some of the few structures which were dosed at 
a dilution factor of 1:4. This was due to attempts in using a dilution factor of 1:2 causing non-viable 
cells throughout the MTT plates and cell lines, with an IC50 value unable to be calculated, also 
suggesting the high potentcy of these compounds. It could be considered that with these compounds 
exhibiting similar low dose responses with low error repeats, they share a similar mode of action once 
















Table 1. Table displaying the mean IC50 values of the 3 MTT repeats for each compound and cell line. 
 
While these low dose similarities may be expected between compounds 2 and 3 due to the small 
structural difference between them (Figure 24), it would be expected that compound 12 may also be 
structurally similar. This is not the case as displayed in Figure 24, whilst compound 12 bears the same 
butylamine chain as compound 3 the rest of the structure is significanty different being one of the two 
iridium complexes. Compound 12 incorporates the guanidine derivatve compound 8, yet there is a 3 
fold increase in the effectiveness of compound 12 when comparing to compound 8 suggesting the 
irdium complex increases toxicity. When comparing to the first iridium complex Compound 11, this 
incorporates the thiourea derivative compound 3, yet an opposite effect is observed being that 
compound 3 exhibits greater sensetivity then compound 11. This MTT data would suggest that it only 
requires a small change between a sulfur ion to an NH group to drastically increase the sensitivity and 
success of the iridium complexes. 














1 3.1 2.7 4.0 4.0 21.7 4.1 
2 0.8 1.0 0.9 2.7 1.4 1.0 
3 1.1 1.4 1.0 1.7 1.2 1.1 
4 13.8 17.8 17.4 18.8 12.8 14.0 
5 2.0 5.5 1.9 2.5 2.9 2.8 
6 29.6 21.3 34.4 32.6 15.1 19.0 
7 22.7 35.4 20.9 33.5 13.4 19.3 
8 8.9 14.4 9.5 12.5 10.8 20.3 
9 5.2 11.9 5.0 12.8 7.4 11.6 
10 9.5 28.9 12.6 28.3 15.2 26.3 
11 13.6 15.5 13.0 15.9 7.1 7.9 
12 1.0 1.6 1.5 1.6 1.4 1.6 
13 14.7 12.8 15.9 14.3 13.2 13.4 




Figure 24. Structures of compounds 1-14. 
Compounds 1, 5 and 10 express the highest error margins in comparison to the remaining compounds. 
There are similar patterns observed in compound 1 through all repeats although these carry 
unacceptable error margins, whilst COLO-704 parental line has a far higher dose response and EFO-21 
resistant subline exhibits consistant low dose data. The inconsistencies in compound 1 may indicate 
several causes including the compound having no specific target, causing cytostatic growth effects of 
the cell lines or there may be a potetntial stability issue of the compound itself. Both benzylamine 
derivatives display some high error margins, compound 5 displays a high level of error in the EFO-27 
reistant subline, whilst it is observed in compound 10 to be in both EFO-21 and EFO-27 resistant 
sublines. As these error margins are only recognised in the sublines it may be that these compounds 




The importance of IC50 values between parental cell lines and cisplatin-adapted sublines must be 
considered when reviewing the MTT data. Compounds 2, 3, 4, 5, 12, 13 and 14 all shared similarities 
in IC50 values between the three parental cell lines and their cisplatin resistant sublines, whilst 
compounds 13 and 14 are observed to have a slightly higher activity in EFO-21 and EFO-27 cisplatin 
resistant sublines, seen throughout all the repeats. The similaraties indicate that these compounds 
are not susceptible to the restant mechanisms presented by the cisplatin reistant sublines, thus 
achieving the same sensitivity as within the parental cell lines. Greater sensitivity in compound 13 and 
14 is displayed in the cisplatin resistant sublines, initially suggesting these two compounds are more 
effective in treating the resistant cell lines then the parental cell lines, and have potentially overcome 
the resistant mechanisms. While this is a promising assement, on closer inspection of the data there 
is not a significant enough difference to come to a firm conclusion when comparing to the whole 
dataset, although these compounds were the only two to display such results. Treating resistant cells 
is a crucial challenge in cancer therapies,83 but these compounds have shown promise in being able to 
tackle the mechanisms presented by these resistant overian cancer sublines. 
While keeping in mind the range of the IC50 values achieved through these assays, it has been 
suggested that an IC50 figure which is between 10-100 μM may not nessessarily be an ideal candidate 
for in vivo studies, due to the quantities of compound which would be required to upscale into the 
human body to observe the same desired effect.55 In this instance compounds 2, 3, 5, 12 and 14 
achieved successful IC50 concentrations below a 10 μM dose in both parental lines and cisplatin 
resistant sublines, and should be considered for further studies. 
Whilst the MTT technique remains an ever popular and confident cell viability assay throughout 
literature, limitations must be considered when studying the data.80 It has been highlighted that in 
some cases, results can be influenced due to compound modifications causing cellular metabolism 
changes,79 but also compound interactions with the MTT dye itself effecting the expression when 
analysing via a plate reader are possible.81 
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Chapter 4: Confocal microscopy of iridium complex compounds 
4.1 Introduction 
Confocal microscopy was used for qualitative assessment of EFO-21 and EFO-27 parental and cisplatin 
resistant sublines when dosed with compound 11 and compound 12, to potentially observe expression 
differences in cellular uptake between the two iridium complexes. As differences were noted between 
compound 11 and compound 12 during MTT viability assays, it would be expected that there are 
uptake differences between the thiourea and guanidine complexes and this may be seen through 
confocal microscopy assays. The Colo-704 cell lines could not be used in this assay due to poor 
adhesion to the cover slips even when using an adhesion activator Poly-l-lysine. 
4.2 Materials and Methods 
Materials 
Iridium complex compounds 11 and compound 12 tested were dissolved in DMSO and stored at room 
temperature prior to the assay.  
The cell lines EFO-21, EFO-27 and COLO-704 were purchased from DSMZ (Braunschweig, Germany). 
The cisplatin-resistant sublines EFO-21rCDDP2000 (adapted to 2,000 ng/mL cisplatin), EFO-27rCDDP2000, 
COLO-704rCDDP1000 were obtained from the Resistant Cancer Cell Line (RCCL) collection 
(https://research.kent.ac.uk/ibc/the-resistant-cancer-cell-line-rccl-collection). All cell lines were 
cultured in IMDM (Gibco™ Life Technologies) which was supplemented with 10% (v/v) foetal bovine 
serum (FBS) (Sigma-Aldrich), 100 IU/mL penicillin (Sigma-Aldrich) and 100 mg/mL streptomycin 
(Sigma-Aldrich). PBS tablets (Oxoid Limited) were used to wash all cell lines prior to dissociation. 
Trypsin (0.25% w/v) (Gibco Life Technologies) was used for dissociation of all adherent cell lines 
cultured in T25 flasks. 24 well plates used during the confocal assays were purchased from Greiner 
Bio-one. Sterile reservoirs, cover slips, and forceps were used from lab supplies and autoclaved prior 




Cells were cultured following methods seen in chapter 3.3.1. Sterile cover slips were added to each of 
the 5 test wells per 24 well plate, with one plate per cell line to minimise contamination. From this 
each cell line was split as following methods from chapter 3.3.1 and were seeded at 5x10ˉ⁴ cells per 
well, with a total well volume of cells/medium at 2ml. Once seeded the cell lines were then dosed with 
compound 11 besides compound 12, with the dose calculated by the average result of IC50 value 
repeats obtained from the MTT assays seen in chapter 3.4 with the averages displayed in Table 2.  
   
  
 
Table 2. Table showing the average IC50 values of compound 11 and 12 against the 4 cell lines used. 
 
3 controls were also set up per cell line. This included control 1 being a negative control with only cells 
and no drug or DMSO. Control 2 being just cells with an addition of DMSO which was comparable to 
the amount of drug dosed in compound 11. Whilst the final control 3 being just cells and an addition 
of DMSO which was comparable to the amount of drug dosed in compound 12, with the plate layout 
observed in Table 3. The DMSO controls 2 and 3 were included to observe whether the solvent may 
impact cell growth when comparing to the ‘just cells’ control 1. Once the plate setup was complete 
the samples were then left to incubate at 37°C/5% CO₂ for 24hrs. 
 
Table 3. Example of the 24 well plate layout for the 4 cell lines. 
 EFO-21 PTL EFO-21 +CDDP EFO-27 PTL EFO-21 +CDDP 
Compound 11 13.60uM 15.50uM 12.97uM 15.85uM 
Compound 12 1.00uM 1.55uM 1.45uM 1.58uM 
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After incubation the cells were assessed for a confluency of at least 40% before use. The medium in 
each well was aspirated followed by washing the cells with 0.5 mL PBS twice. After the PBS wash, the 
cells were then fixed with 0.3 mL of 4% paraformaldehyde in PBS solution and left to sit at room 
temperature for 15-20 minutes followed by a further PBS wash repeated 3 times. The slides were then 
removed from the 24 well plates and mounted on microscope slides cell side face down with Prolong 
Diamond Antifade Mountant and DAPI (4′,6-Diamidine-2′-phenylindole dihydrochloride) between the 
two slides. The samples were then left to dry for 10 hours in a light protected box prior to imaging on 
a Zeiss Leica LSM880 confocal microscope using x63 magnification and an oil immersion lens.  
4.3 Results 
The brightness, gain and excitation of the confocal microscopes laser for compound expression was 
kept consistent throughout the assays, although slight adjustments were made to the brightness of 
the DAPI stain to achieve a clear nuclei mapping image. The DMSO control images for all cell lines and 
compounds were taken whilst the blue (DAPI) and green (Compound 11 + 12) spectra were 
highlighted, with only the nuclei DAPI stain fluorescing in the images this suggests that any green 
fluorescence seen in the compound additions will only be from the uptake of either compound.   
Figure 25 depicts results from ‘control 1 - Just cells’, the nuclei expression for all four cell lines grown 
in standard conditions as seen throughout the MTT assays with no additions of either compounds or 
DMSO. The slight difference in the distribution of cells seen between EFO-21 PTL and the rest of the 
cell lines was due to slight confluency differences of the plate wells. These images resemble expected 













Figure 25. Control 1- Just cells control grown in normal conditions with no addition of DMSO or compound. 
 
Figure 26 highlights EFO-21 PTL when dosed with compounds 11 and 12 using the IC50 value achieved 
during MTT viability assays. The DMSO control suggests this cell line is not affected by the volume of 
solvent used in the addition of compound and the nucleus share the same morphology seen in control 
1. The expression of both compounds observes uptake into the cells being clear in the overlay of 
compound/DAPI being a complete cell. Whilst a qualitative assessment of these images would suggest 






























Figure 26. EFO-21 PTL cell line subject to compound 11 and compound 12 dosed at the IC50 concentrations 
achieved via MTT assays. 
 
Figure 27 depicts EFO-21 +CDDP subline when dosed with compounds 11 and 12 using the IC50 value 
achieved during MTT viability assays. The DMSO control is consistent with control 1 suggesting this 
resistant subline is not affected by the volume of solvent applied in the addition of compound. A 
qualitative assessment of Figure 27 suggests similarities seen in the EFO-21 parental line, whereby 



















Figure 27. EFO-21 +CDDP subline subject to compound 11 and compound 12 dosed at the IC50 concentrations 
achieved via MTT assays. 
 
Figure 28 illustrates EFO-27 PTL when dosed with compounds 11 and 12 at the IC50 value achieved 
during MTT viability assays. When comparing the DMSO control and ‘just cells’ control 1 the 
similarities in nuclei morphology would suggest this parental line is unaffected by the volume of 
solvent used in the addition of compounds. A qualitative assessment of this parental line shares 
similarities with both EFO 21 cell lines seen in Figure 26 and Figure 27, where by a greater uptake of 

















Figure 28. EFO-27 PTL cell line subject to compound 11 and compound 12 dosed at the IC50 concentrations 
achieved via MTT assays. 
 
Figure 29 presents the confocal images from EFO-27 + CDDP subline when dosed with compounds 11 
and 12 at the IC50 value acquired during MTT viability assay. As seen in all other cells lines the DMSO 
control conforms to morphology similarities displayed in control 1, suggesting this resistant subline is 
not affected by the volume of solvent used in the addition of compound. The qualitative assessment 
of this resistant subline observes an increase in uptake of compound 11 when comparing to the 
previous cell/sublines, although overall the confocal image would suggest there is greater uptake seen 
















Figure 29. EFO-27 +CDDP subline subject to compound 11 and compound 12 dosed at the IC50 
concentrations achieved via MTT assays. 
 
4.4 Discussion 
Evaluation of the iridium complexes 11 and 12 through 2D confocal microscopy achieved the unveiling 
of additional qualitative data to complement chapter 3. Throughout the images in chapter 4.3, all 
negative controls confirm that the fluorescence observed in the complete cell images were true to the 
compounds excitation and not due to non-specific staining. These images also imply both compound 
11 and 12 to be primarily localised to the cytoplasm, suggesting either compound has not passed the 
outer nuclear membrane in all parental and resistant cell lines. Although we must consider that due 
to the fact these images are 2D we cannot guarantee there may not be small localised areas of either 
compound within the nucleus. This would require further analysis of the cells through methods 
involving 3D imaging to observe in-depth analysis into the nuclei compartments.76 
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When relating the intensity of fluorescence in the confocal images to the MTT data collected in 
chapter 3.5.1 similarities can be observed and considered as a qualitative tool. Whilst comparing IC50 
values between the iridium complexes against all parental and resistant cell lines, it is noted that the 
guanidine variant compound 12 has greater dose sensitivity when comparing to the thiourea bearing 
compound 11. The confocal images somewhat support the higher dose sensitivity, with an increase of 
fluorescence emission and greater distribution of compound 12 within all cell lines suggesting this 
iridium derivative has greater efficiency/potency. 
Observed mainly in both EFO-27 parental cell line and cisplatin resistant subline dosed with compound 
11, are localised areas of compound appearing as intense fluorescent dots. Whilst further analysis 
would be required to depict what may cause these areas, it may be possible the cells are potentially 
preparing/packaging the compound for further use. 
Confocal microscopy was a useful tool in which we could observe the uptake of the iridium complexes 
within the cell lines and make comparisons to MTT data, but it must be considered that prolonged 
exposure to the confocal microscopes laser can cause potential photobleaching, and fluorescence 












Chapter 5: General Discussions and Outlook 
 
5.1 General discussion and conclusions 
Firstly, within chapter 2 14 compounds were successfully synthesised some of which being novel 
structures to be screened against a panel of ovarian cancer cell lines. This included 6 derivatives of 
thiourea, 4 derivatives of guanidine, and an additional 4 compounds supplied by Barbora Balonova as 
part of her research towards OLED technology,82 2 compounds of which being iridium complexes. Due 
to time pressures the synthesis methods could not be optimised with some thiourea and guanidine 
derivatives achieving yields as low as 15% during their final synthesis steps. Although some low yields 
were collected, both sets of derivatives were successfully characterised through ¹H NMR (400MHz), 
¹³C NMR (125MHz), Mass Spectrometry, Elemental Analysis and Melting Point analysis. 
In Chapter 3, the compounds synthesised within the previous chapter were screened via an MTT cell 
viability assay against a panel of human ovarian cancer cell lines; EFO-21, EFO-27 and COLO-704 were 
all examined in their parental cell line and cisplatin resistance subline variants. Apart from the starting 
compound (1) which displayed high error margins, all the compounds displayed promising results from 
the viability assay with low error margins and dose strengths required to achieve IC50 values ranging 
from 0.8-35μM. The most efficient data was achieved in a mix of thiourea and guanidine derivatives 
including compounds 2, 3, 5, 12 and 14 achieving successful IC50 concentrations below a 10 μM dose 
in both parental lines and cisplatin resistant sublines and should be considered for further studies. 
Chapter 4 allowed us to observe the uptake of both iridium complexes (compound 11 and 12) within 
the parental lines and cisplatin resistant sublines of EFO-21 and EFO-27. We were able to harness the 
fluorescence properties of each complex whilst also collecting qualitative data which complemented 
the MTT analysis in the previous chapter. It was found that the compounds were primarily localised 
to the cytoplasm of all cell lines, whilst also noting a higher fluorescence activity of compound 12 




To conclude, the investigated thiourea and guanidine derivatives uncovered promising low dose 
responses in the early research stages of human in vitro cell assays, with the data collected providing 
a start to new potential therapeutic pathways in the battle against cancer resistant ovarian cell lines. 
5.2 Future Work 
Due to time constraints within this project we were unable to optimise the synthesis of our derivatives 
resulting in low yields of some thioureas and guanidines, being an area to improve to maximise purity 
and efficiency of the synthesis methods. To further understand the effects that these compounds have 
on human ovarian cancer cells, carrying out an assay such as a Western Blot pre and post dosing the 
cells with each compound, may reveal possible protein targeting and assist in understanding the 
mechanism of action for these structures. Furthering from this, pharmacokinetic and 
pharmacodynamics studies of our compounds would give an insight into the possible in vivo impact 
these structures may have and potential barriers they may be presented with. 
To further the confocal analysis of cell lines EFO-21 PTL and EFO-27 PTL dosed with both iridium 
complexes, it would be beneficial to include observations of the uptake difference between various 
compound concentrations. Alongside the IC50 value it would be constructive to include the IC90 
values which would select for the more resistant cells, but also the IC10 concentration to select for 
those cells which would be under less stress. Additionally, 3D imaging methods would complement 
the 2D imaging to observe the spread of compound throughout the cell, and differentiate between 
any variations in compound density throughout all regions of the cell. 
In the final weeks of this project, we conducted antibiotic susceptibility assays using wild type E. coli 
cells dosed with all 14 compounds to determine potential antimicrobial effects. Unfortunately, the 
data was inconclusive but should be considered for retesting with an optimised method to compliment 
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Appendix: Supplementary Information 
 
1H NMR’s: 
Figure S1. Compound 1: 
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